{"organizations": [], "uuid": "37e6eb00071489a0ea3729f71d4b5108de1d5cac", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-announces/brief-paratek-pharmaceuticals-announces-proposed-private-offering-of-125-mln-of-convertible-senior-subordinated-notes-due-2024-idUSASC09WC1", "country": "US", "domain_rank": 408, "title": "BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.078, "site_type": "news", "published": "2018-04-19T04:12:00.000+03:00", "replies_count": 0, "uuid": "37e6eb00071489a0ea3729f71d4b5108de1d5cac"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-paratek-pharmaceuticals-announces/brief-paratek-pharmaceuticals-announces-proposed-private-offering-of-125-mln-of-convertible-senior-subordinated-notes-due-2024-idUSASC09WC1", "ord_in_thread": 0, "title": "BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-paratek pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "paratek pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - Paratek Pharmaceuticals Inc:\n* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024\n* PARATEK PHARMACEUTICALS-INTENDS TO USE PROCEEDS, TOGETHER WITH EXISTING CAPITAL RESOURCES, TO FUND ONGOING AND FUTURE CLINICAL STUDIES OF OMADACYCLINE Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T04:12:00.000+03:00", "crawled": "2018-04-19T15:23:26.026+03:00", "highlightTitle": ""}